New JAMA Health Forum article lays the foundation for a comprehensive national testing strategy that will promote better collaboration between public health and diagnostic laboratories and test manufacturers.
AMP encourages robust variant data sharing through public repositories to help address health inequities, advance precision medicine, and improve clinical diagnosis and care for patients with cancer and rare inherited disorders.
AMP has announced the results of its recent elections for 2021 Leadership positions. AMP is an organization driven by the dedication of its volunteers and looks forward to working with these newly elected leaders.
Latest joint consensus guideline authored by representatives from AMP, CAP, Royal Dutch Pharmacists Association, and European Society for Pharmacogenomics and Personalized Therapy
Legislation would enhance transparency, preserve innovation, and ensure broad patient access
to essential laboratory developed testing procedures
Survey reveals that current payment systems do not account for all of the time spent by qualified healthcare professionals to interpret and integrate results within the context of a patient’s diagnosis
Laboratory staffing and supply shortages are limiting patient access to critical cancer screening tests that guide treatment decisions
New AMP COVID Response Steering Committee will lead the organization’s cross-functional effort to address clinical needs and ensure more Americans have timely access to high-quality testing procedures
Demand for COVID-19 diagnostic testing continues to rise as clinical laboratories face significant staffing shortages and persistent supply chain issues
Dennis Lo, Karen Mann & Ronald Przygodzki Honored for Contributions to the Field & Molecular Pathology Community
Modernizing the CLIA Regulations is the Best Approach to Ensuring High Quality and Rapid Response Testing
AMP has announced the results of its recent elections for 2020 Leadership positions. AMP is an organization driven by the dedication of its volunteers and looks forward to working with these newly elected leaders.
AMP stands in solidarity with the Black community in this fight against racial inequality and race-based violence. We strongly condemn systemic racism and the recent acts of violence.
More than 100 clinical laboratory professionals across the US provide feedback on COVID-19 diagnostic testing environment and offer recommendations to improve future pandemic responses
Latest joint guideline from AMP and CAP completes series of three reports designed to aid assay design, increase concordance across laboratories and improve patient care.
AMP recommends remedies to address consequences of recent FDA actions and improve patient care.
AMP has announced the recipients of this year’s Award for Excellence in Molecular Diagnostics, Jeffrey A. Kant Leadership Award and Meritorious Service Award. These prestigious accolades will be presented this November during AMP’s 25th Annual Meeting & Expo.
Key recommendations include well established clinical validity and comprehendible test reports for healthcare providers
AMP has announced the results of its recent elections for 2019 Leadership positions. AMP is an organization driven by the dedication of its volunteers and looks forward to working with these newly elected leaders.
Updated position statement reflects emerging technology landscape, highlights privacy best practices, and expands conditions for clinically-meaningful tests
Draft legislation would overturn 150 years of patent case law, prevent the development of life-saving diagnostics for devastating diseases, dramatically increase drug costs, and significantly limit access to optimal patient care
A new joint report from AMP and CAP shares consensus, evidence-based recommendations to aid in the design and validation of clinical CYP2C9 assays, promote standardization of testing across different laboratories and improve patient care.
Stakeholders urge the Centers for Medicare and Medicaid Services (CMS) to revise its interpretation of the National Coverage Determination (NCD) for Next Generation Sequencing (NGS), expressing serious concerns that the overly broad interpretation will restrict patient access to medically necessary and relevant clinical tests and adversely impact cancer care and outcomes.
AMP has announced the recipients of this year’s Award for Excellence in Molecular Diagnostics, Jeffrey A. Kant Leadership Award and Meritorious Service Award. These prestigious accolades will be presented in November during the AMP 2018 Annual Meeting in San Antonio, Texas.
AMP has published consensus, evidence-based recommendations to aid clinical laboratory professionals with the management of most Chronic Myeloid Neoplasms (CMNs) and development of high-throughput pan-myeloid sequencing testing panels. The report, “Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms (CMNs): A Report of the Association for Molecular Pathology,” was released online ahead of publication in The Journal of Molecular Diagnostics.
AMP has announced the results of its recent elections for 2019 Leadership positions. AMP is an organization driven by the dedication of its volunteers and looks forward to working with these newly elected leaders.
AMP has published consensus, evidence-based recommendations to aid clinical laboratory professionals when designing and validating clinical CYP2C19 assays, promote standardization of testing across different laboratories and complement existing clinical guidelines.
The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have updated their joint 2013 evidence-based guideline to ensure that clinicians stay apace with rapid advancements and provide optimal patient care.
Cooperation Will Harness Expertise from Emerging Field of Molecular Pathology to Broaden ASCO’s CancerLinQ® Platform
Latest report completes series of best practice guidelines designed to improve entire NGS workflow and ensure optimal results for better patient care.
AMP has announced the recipients of the Jeffrey A. Kant Leadership Award and the AMP Meritorious Service Award. Together with the AMP Award for Excellence in Molecular Diagnostics, these awards will be presented at the AMP 2017 Annual Meeting.
Epigenetics pioneer to receive Association's highest honor at upcoming Annual Meeting
AMP announced the results of its 2017 Leadership Elections. AMP is an organization driven by the dedication of its volunteers and looks forward to working with these newly elected leaders.
AMP's consensus recommendations will help clinical laboratory professionals achieve high-quality sequencing results and deliver better care for cancer patients.
This pivotal guideline addresses a wide range of molecular markers appropriate for testing in patients with early and advanced colorectal cancer. The guideline will aid in establishing standard molecular marker testing to help guide targeted therapy decisions, and advance personalized care for colorectal cancer patients.
Clinical laboratory and oncology experts collaborate to publish evidence-based somatic variant classification system to improve patient care
Organization of molecular diagnostics professionals reaffirms commitment to preserving broad access to essential patient care.
AMP has announced a new report that examines how sophisticated technology advancements are being implemented to improve diagnosis and optimize treatment selection for multiple invasive, opportunistic and often deadly infectious diseases. The manuscript titled “Emerging and Future Applications of MALDI-TOF Mass Spectrometry in the Clinical Microbiology Laboratory: A Report of the Association for Molecular Pathology” has been released online ahead of publication in the November 2016 issue of The Journal of Molecular Diagnostics.
AMP has announced the recipients of the Jeffrey A. Kant Leadership Award and the AMP Meritorious Service Award. Together with the AMP Award for Excellence in Molecular Diagnostics, these awards will be presented at the AMP 2016 Annual Meeting.
AMP recently participated in two events designed to help educate lawmakers and congressional staff about laboratory developed procedures (LDPs) and the vital role they play in precision medicine and patient care. Both the U.S. Senate Committee on Health, Education, Labor & Pensions (HELP) Hearing and the Co-hosted Congressional Briefing provided bipartisan forums for AMP leaders to discuss how LDPs are currently designed, validated, regulated, and used in a variety of clinical settings.
Association's highest honor for lifetime of achievements to be presented during Annual Meeting
"As one of the true early pioneers of the human genome, Dr. Eric Lander is a well-deserved recipient of the AMP Award for Excellence in Molecular Diagnostics," said Charles E. Hill, MD, PhD, AMP President.. "Throughout his career, Dr. Lander and his colleagues have developed tools and applied methods that have transformed our understanding of the molecular basis of rare and common genetic diseases, including cancer. His seminal publications, fundamental discoveries, and significant scientific contributions have had a massive impact on human health by providing us with the framework for the modern practice of clinical molecular diagnostics."
New JMD report recognizes value of testing procedures and promotes paradigm corrections to drive widespread adoption of a more proactive, patient-centered approach to modern healthcare
“Molecular pathology testing procedures are vital tools for insight and analysis into various aspects of clinical practice,” said Roger D. Klein, MD, JD, AMP Professional Relations Chair. “However, we need a more practical and patient-centered approach for evaluating clinical usefulness before we can truly deliver the promise of precision medicine.”
New publication in The Journal of Molecular Diagnostics describes cost and value analysis of gene panels including non-small cell lung cancer, exome sequencing, and hearing loss gene panels
"Genomic Sequencing Procedures are changing the way clinicians are diagnosing and managing hereditary diseases and the delivery of oncology care," said Linda Sabatini, PhD, HCLD, First Author and Project Leader, Director of Molecular Diagnostics at NorthShore University HealthSystem. "We hope that laboratories will use these tools to assess their individual costs, to consider the value structure in their own patient populations, and to contribute their data to the ongoing dialogue regarding the impact of GSPs on improving patient care."
AMP is very concerned and disappointed to see the FDA taking enforcement action against the physicians at Texas Children's Hospital and Houston Methodist Hospital for their laboratory developed procedure (LDP) for Zika virus, which was designed to identify virus-specific RNA sequences in a large metropolitan area. Given the ongoing outbreak of the infection and risk of infection in the Houston area, these types of tests are critical for patient care and should be made available to these patients in need.
New report published in The Journal of Molecular Diagnostics focuses on improving pathology training programs for molecular pathology and genomic medicine
The AMP paper provides residency programs with specific recommendations from subject matter experts on 10 major molecular pathology topics: basic molecular pathology goals and laboratory management; basic concepts in molecular biology and genetics; technology; inherited disorders; oncology; infectious diseases; pharmacogenetics; histocompatibility and identity; genomics, and information management.
Advances in Molecular Testing Offer New Hope for Lung Cancer Patients
Report to AMA documents the challenges, related technology, and proposed coding scheme for GSAs
Report provides overview of possibilities, challenges, and applications of next-generation sequencing
Case Challenges Patents as Dangerous Roadblock to Patient Care, Medical Innovation
The record-breaking number of abstract submissions for the AMP 2012 Annual Meeting on Genomic Medicine is consistent with the increased number of exhibiting companies and anticipated number of attendees.
Proposal to be completed by the end of June and released for feedback from stakeholders in the laboratory and payer community before submission of a formal proposal to the AMA CPT Editorial Panel.
The goal of the group is to produce a white paper that will outline the key issues, and provide AMP's recommendations for future LDT oversight.
AMP is optimistic that it will ultimately prevail in its lawsuit to invalidate patents on two genes that are known to cause breast cancer.
AMP is encouraged by the Court's recognition that Prometheus patents neither promote the advancement of medical practice, nor benefit patient care.
AMP testified at the U.S. Patent and Trademark Office hearing regarding patents on human genes.
AMP adopts change in governance structure as part of newly implemented strategic plan.
Gold Partner
Diamond Partner
Diamond Partner
Platinum Partner
Gold Partner
Gold Partner
Gold Partner
Gold Partner
Gold Partner
Gold Partner
Gold Partner
Gold Partner
Gold Partner
Gold Partner
Gold Partner
Gold Partner
Gold Partner
Gold Partner
Diamond Partner
Diamond Partner
Silver Partner
Silver Partner
Silver Partner
Silver Partner
Silver Partner
Silver Partner
Silver Partner
Silver Partner